Search

Your search keyword '"Trivizki, Omer"' showing total 193 results
Start Over Author "Trivizki, Omer"
193 results on '"Trivizki, Omer"'

18. The Impact of Carotid Endarterectomy on Choriocapillaris Perfusion

Author

Zhou, Sandy W., primary, Zhang, Yi, additional, Noam, Natalie, additional, Rabinovitch, David, additional, Bar, Davidov, additional, Yousif, Basheer S., additional, O'Brien, Robert, additional, Hiya, Farhan E., additional, Lin, Yufen, additional, Berni, Alessandro, additional, Gregori, Giovanni, additional, Wang, Ruikang K., additional, Rosenfeld, Philip J., additional, and Trivizki, Omer, additional

Published
2023
Full Text
View/download PDF

19. Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID‐19 pandemic lockdowns: A large cohort.

Author

Barequet, Dana, Shor, Reut, Segal, Ori, Greenbaum, Eran, Trivizki, Omer, Loewenstein, Anat, and Rabina, Gilad

Subjects
STAY-at-home orders, VISUAL acuity, COVID-19 pandemic, MACULAR degeneration, ENDOTHELIAL growth factors
Abstract

Purpose: To evaluate the impact of the changes in treatment patterns before, during and after the COVID‐19 pandemic on best‐corrected visual acuity (BCVA) in previously treated neovascular age‐related macular degeneration (nAMD) patients. Methods: A multi‐centre, retrospective, observational study of consecutive nAMD patients during 2019–2021. Data collected included demographics, BCVA, dates of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) injections and clinic visits. Results: A total of 1652 eyes of 1652 nAMD patients were included, out of which 850 eyes were assessed in 2019 (pre‐COVID‐19), 630 eyes were assessed in 2020 (COVID‐19) and 974 eyes were assessed in 2021 (post‐COVID‐19). During the COVID‐19 period, the mean number of anti‐VEGF injections was significantly lower than the corresponding pre‐COVID‐19 and post‐COVID‐19 periods (5.55 compared to 6.13 and 6.60, respectively p < 0.01). A constant lower ratio of injections per patient/month was observed during COVID‐19 compared to previous and following years, with a notable decline during March–April, reaching a ratio of 0.4 in 2020 versus 0.65 in 2019 and 0.62 in 2021 (p < 0.01). Baseline BCVA (0.825, p < 0.001), number of injections (−0.007, p < 0.001), gender (−0.027, p = 0.037) and age (0.004, p < 0.001) were shown to be significant predictors of final BCVA. Conclusion: During the COVID‐19 period, patients were treated with significantly less intravitreal anti‐VEGF injection compared to the previous year with compensation in the following year. These changes in treatment patterns did not have a significant impact on BCVA outcomes. Age, gender, baseline BCVA and number of injections are predictors of final visual outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography

Author

Shen, Mengxi, primary, Zhou, Hao, additional, Lu, Jie, additional, Li, Jianqing, additional, Jiang, Xiaoshuang, additional, Trivizki, Omer, additional, Laiginhas, Rita, additional, Liu, Jeremy, additional, Zhang, Qinqin, additional, de Sisternes, Luis, additional, Feuer, William J., additional, O'Brien, Robert, additional, Gregori, Giovanni, additional, Wang, Ruikang K., additional, and Rosenfeld, Philip J., additional

Published
2023
Full Text
View/download PDF

24. How OCT is improving early characterization of GA lesions.

Author

Liang Wang, Rosenfeld, Philip J., and Trivizki, Omer

Subjects
RETINAL anatomy, OPTICAL coherence tomography, RETINAL degeneration, VISUAL pigments, RETINAL diseases, QUALITY assurance, EARLY diagnosis, PHOTORECEPTORS
Published
2024

25. Influence of Carotid Endarterectomy on Choroidal Perfusion

Author

Zhang, Yi, primary, Zhou, Sandy Wenting, additional, Noam, Natalie, additional, Rabinovitch, David, additional, Bar, Davidov, additional, Yousif, Basheer Sheick, additional, O’Brien, Robert, additional, Gregori, Giovanni, additional, Wang, Ruikang K., additional, Rosenfeld, Philip J., additional, and Trivizki, Omer, additional

Published
2023
Full Text
View/download PDF

27. Onset and Progression of Persistent Choroidal Hypertransmission Defects in Intermediate AMD: A Novel Clinical Trial Endpoint

Author

Liu, Jeremy, primary, Shen, Mengxi, additional, Laiginhas, Rita, additional, Herrera, Gissel, additional, Li, Jianqing, additional, Shi, Yingying, additional, Hiya, Farhan, additional, Trivizki, Omer, additional, Waheed, Nadia K., additional, Chung, Carol Y., additional, Moult, Eric M., additional, Fujimoto, James G., additional, Gregori, Giovanni, additional, and Rosenfeld, Philip J., additional

Published
2023
Full Text
View/download PDF

35. SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY DETECTION OF BRUCH MEMBRANE AND CHORIOCAPILLARIS ABNORMALITIES IN SORSBY MACULAR DYSTROPHY

Author

Iyer, Prashanth G., primary, Zhou, Hao, additional, Zhang, Qinqin, additional, Chu, Zhongdi, additional, Shen, Mengxi, additional, Shi, Yingying, additional, Liu, Jeremy, additional, Trivizki, Omer, additional, Lam, Byron L., additional, Wang, Ruikang K., additional, Gregori, Giovanni, additional, and Rosenfeld, Philip J., additional

Published
2022
Full Text
View/download PDF

44. COVID-19 Pandemic Lockdowns' Impact on Visual Acuity of Diabetic Macular Edema: A Large Cohort.

Author

Gomel, Nir, Shor, Reut, Lippin, Naama, Segal, Ori, Greenbaum, Eran, Schwartz, Shulamit, Trivizki, Omer, Loewenstein, Anat, and Rabina, Gilad

Subjects
MACULAR edema, VISUAL acuity, STAY-at-home orders, COVID-19 pandemic, COVID-19
Abstract

Introduction: The objective of this study was to evaluate the impact of unplanned treatment gap, secondary to COVID-19 pandemic lockdowns, on visual acuity in previously treated diabetic macular edema (DME) patients. Methods: A multicenter, retrospective study of DME patients, previously treated with anti-VEGF injections, who were followed up during COVID-19 pandemic (2020) compared to pre-CO-VID-19 period (2019). Results: A total of 634 DME patients with a mean age of 68.4 years met the inclusion criteria, 385 were assessed in 2019 (pre-COVID-19) and 239 patients assessed in 2020 (COVID-19). Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively). There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07). Mean number of anti-VEGF injections was significantly lower (5 vs. 6, p < 0.01), with a major lower ratio of injections per patient in the COVID-19 first lockdown period (March–June 2020) in the COVID-19 group. Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA. Number of injections, age, gender, and the year were not found as predictors of final BCVA. Conclusions: In a large cohort of DME patients, an unplanned delay in treatment with anti-VEGF injections for 2–3 months, due to COVID-19 pandemic lockdown, had no significance impact on visual acuity. For most patients, returning to routine treatment regimen was sufficient for maintaining BCVA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Choroidal Changes in Eyes With Polypoidal Choroidal Vasculopathy After Anti-VEGF Therapy Imaged With Swept-Source OCT Angiography

Author

Shen, Mengxi, primary, Zhou, Hao, additional, Kim, Kiyoung, additional, Bo, Qiyu, additional, Lu, Jie, additional, Laiginhas, Rita, additional, Jiang, Xiaoshuang, additional, Yan, Quan, additional, Iyer, Prashanth, additional, Trivizki, Omer, additional, Shi, Yingying, additional, de Sisternes, Luis, additional, Durbin, Mary K., additional, Feuer, William, additional, Gregori, Giovanni, additional, Wang, Ruikang K., additional, Sun, Xiaodong, additional, Wang, Fenghua, additional, Yu, Seung-Young, additional, and Rosenfeld, Philip J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results